Prevention of *Staphylococcus aureus* Infections by Glycoprotein Vaccines Synthesized in *Escherichia coli*

Michael Wacker,1 Linhui Wang,2,3 Michael Kowarik,1 Meghan Dowd,2 Gerd Lipowsky,1 Amir Faridmoayer,1 Kelly Shields,2 Saeyoung Park,2 Cristina Alaimo,1 Kathryn A. Kelley,2 Martin Braun,1 Julien Quebatte,1 Veronica Gambillara,1 Paula Carranza,1 Michael Steffen,1 and Jean C. Lee2

1GlycoVaxyn, Schlieren, Switzerland; 2Division of Infectious Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts; and 3School of Life Science and Biotechnology, Dalian University of Technology, China

**Background.** *Staphylococcus aureus* is a leading cause of superficial and invasive human disease that is often refractory to antimicrobial therapy. Vaccines have the potential to reduce the morbidity, mortality, and economic impact associated with staphylococcal infections. However, single-component vaccines targeting *S. aureus* have failed to show efficacy in clinical trials.

**Methods.** A novel glycoengineering technology for creation of a multicomponent staphylococcal vaccine is described. Genes encoding *S. aureus* capsular polysaccharide (CP) biosynthesis, PglB (a *Campylobacter* oligosaccharyl transferase), and a protein carrier (detoxified *Pseudomonas aeruginosa* exoprotein A or *S. aureus* α toxin [Hla]) were coexpressed in *Escherichia coli*. Recombinant proteins N-glycosylated with *S. aureus* serotype 5 or 8 CPs were purified from *E. coli*.

**Results.** Rabbits and mice immunized with the glycoprotein vaccines produced antibodies that were active in vitro in functional assays. Active and passive immunization strategies targeting the CPs protected mice against bacteremia, and vaccines targeting Hla protected against lethal pneumonia. The CP-Hla bioconjugate vaccine protected against both bacteremia and lethal pneumonia, providing broad-spectrum efficacy against staphylococcal invasive disease.

**Conclusions.** Glycoengineering technology, whereby polysaccharide and protein antigens are enzymatically linked in a simple *E. coli* production system, has broad applicability for use in vaccine development against encapsulated microbial pathogens.

**Keywords.** *Staphylococcus aureus*; capsular polysaccharides; bioconjugate vaccine; glycoprotein; bacteremia; pneumonia; animal infection models; glycoengineering.
forming toxin to which lymphocytes, macrophages, alveolar epithelial cells, pulmonary endothelium, and erythrocytes are susceptible [10]. A genetically detoxified protein (HlaH35L) is defective in pore formation, and antibodies to HlaH35L neutralize the lytic activity of native Hla [11]. Immunization with HlaH35L protects mice against lethal staphylococcal pneumonia, lethal peritonitis, and skin infections [12–14].

Immunization with conserved staphylococcal protein antigens glycosylated with CPs may be an elegant and efficient strategy to prevent S. aureus infections, limiting the numbers of individual vaccine components that need to be prepared and individually purified. Such an approach is feasible through the development of a novel *Escherichia coli* N-linked glycosylation technology [15, 16], wherein O antigens are transferred to specific sites within a protein carrier by the oligosaccharyltransferase PglB [15–17]. In contrast to chemically conjugated vaccines, bioconjugate vaccines are homogenous with a defined molecular structure, and the protein and glycan components are kept in native conformations, avoiding denaturation of essential B-cell epitopes [18]. The product contains peptide and covalently linked sugar epitopes from the same organism, thereby broadening its efficacy against numerous manifestations of microbial disease.

We have prepared glycoconjugate vaccines composed of CP5–*Pseudomonas aeruginosa* exoprotein A (Epa), CP8-Epa, and CP5-Hla and evaluated their protective efficacy against bacteremia and lethal pneumonia in mice. Whereas CP5-Epa and CP8-Epa significantly reduced bacteremia, the CP5-Hla bioconjugate vaccine protected against both bacteremia and lethal pneumonia.

**METHODS**

**Expression of CP5 and CP8 in *E. coli* and Bioconjugate Vaccine Production**

The bacterial strains, plasmid constructs, primers, and details of bioconjugate vaccine preparation are provided in the Supplemental Methods. Briefly, genes from the *P. aeruginosa* O11 O antigen gene cluster (*wzz* to *wpbM*) were amplified by polymerase chain reaction and cloned in a plasmid with *S. aureus cap5HIJK* or *cap8HIJK*. Recombinant plasmids were introduced into *E. coli* strains with mutations in lipopolysaccharide and enterobacterial antigen expression, resulting in expression of CP5 and CP8 in *E. coli*. Epa was modified for detoxification [19], replacement of the N-terminal signal peptide with the *E. coli* DsbA signal peptide, addition of 2 glycosylation consensus sequences [20], and insertion of a C-terminal hexahistidine tag. An expression plasmid for recombinant expression of HlaH35L with 1 glycosite and a signal sequence for periplasmic localization was designed on the basis of the published [11, 21] and detoxified version of *S. aureus* Hla.

Plasmids containing PglB and Epa or Hla were transformed into *E. coli* cells expressing CP5 or CP8. *E. coli* containing the recombinant plasmids were grown to logarithmic phase, and expression of PglB and either Epa or Hla was induced by addition of 1 mM IPTG and 0.2% arabinose. After overnight incubation at 37°C, the *E. coli* were harvested, and the bioconjugates were extracted by osmotic shock or high-pressure homogenization [15, 16]. The bioconjugate vaccines were purified by immobilized metal affinity, anionic exchange, hydroxyapatite, and size-exclusion chromatography as detailed in the Supplementary Methods.

**Bacterial Cultures**

*S. aureus* strains Reynolds (CP5), Reynolds (CP8), and Newman were described previously [9, 22]. *S. aureus* strains LAC and ST80 are community-associated MRSA isolates [23, 24]. Strains NRS 382 (USA100) and NRS 383 (USA200) are hospital-associated MRSA strains obtained from the Network on Antimicrobial Resistance in *Staphylococcus aureus* program, which is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (contract HHSN272200700055C). For bacteremia studies and opsonophagocytic killing (OPK) assays, *S. aureus* strains were cultivated for 24 hours at 37°C on Columbia agar (Difco Laboratories) supplemented with 2% NaCl [9]. For pneumonia studies, staphylococci were harvested from tryptic soy broth (Difco) cultures grown to the logarithmic phase of growth, as described elsewhere [25].

**OPK Assays**

Human blood was collected from healthy volunteers, who provided written informed consent as approved under institutional guidelines. The conventional OPK assay (0.5 mL volume) was performed with human neutrophils as described [26]. The microtiter-based OPK assay was based on that described by Burton and Nahm [27]. HL-60 cells (ATCC) were used after low passage (<3 months) and maintained in L-glutamine-containing Roswell Park Memorial Institute 1640 medium (Mediatech) supplemented with 10% heat-inactivated fetal bovine serum (HyClone), 100 U/mL penicillin, 100 µg/mL streptomycin, and 0.25 µg/mL amphotericin (Mediatech). The cells were differentiated to granulocytes with N,N-dimethylformamide as described elsewhere [27], and their phenotype was confirmed by flow cytometry [27]. The assay was performed in 96-well plates, and each well (volume, 80 µL) contained 4 × 10⁵ HL60 cells, 10⁶ colony-forming units (CFU) of *S. aureus*, rabbit immunoglobulin G (IgG) or mouse serum, and 1% guinea pig serum (Cedarlane) as a complement (C′) source. After incubation for 2 hours at 37°C with shaking, HL60 cells were lysed by the addition of 20 µL of 1% Triton X-100. The samples were plated in duplicate, and the killing effect was defined as the reduction in CFU per milliliter after 2 hours, compared with the concentration at time 0.

**Hla Neutralization Assay**

Hla (4 HU/mL; Toxin Technology) was incubated for 1 hour with serial 2-fold dilutions of serum from immunized mice. An equal
volume of washed 2% rabbit erythrocytes was added and incubated for 60 minutes. The samples were centrifuged at 200 × g for 10 minutes, and the OD545 nm of the supernatants was measured. The percentage hemolysis of each sample was compared to that for erythrocytes lysed with 4 HU of Hla. The 50% inhibition titer was calculated using nonlinear regression for sigmoidal curves with variable slopes (by means of Prism 4 software).

Animal Infection Studies
Animal studies were conducted according to Institutional Animal Care and Use Committee guidelines. Swiss-Webster mice (purchased from Taconic Farms or Charles River Laboratories) were vaccinated on days 0, 14, and 28 by the subcutaneous route. Control animals received an irrelevant Shigella O-antigen bioconjugate vaccine (O1-Epa or 2a-Epa). EPA-conjugates were formulated with Alhydrogel, and CP5-Hla was formulated with Adju-Phos to obtain a final Al3+ concentration of 0.06%.

Blood samples were obtained from mice before each vaccination and before bacterial challenge. Sera diluted 1:100 were tested by enzyme-linked immunosorbent assay (ELISA) in microtiter plates coated with purified CPs (4 µg/mL) coupled to poly-L-lysine [28] or native Hla (1 µg/mL). Two weeks after the last vaccination, mice were inoculated by the intraperitoneal route with S. aureus, and quantitative blood cultures were performed 2 hours after challenge [9]. Weight loss and renal infection were evaluated on day 4, and culture data were analyzed by the Mann–Whitney U test. Mice were inoculated by the intranasal route for the lethal pneumonia model [25], and survival data were analyzed using the log-rank test (by means of Prism 4 software).

For passive immunization against bacteremia, mice were given rabbit IgG (300 µg–1 mg) intravenously 24 hours before challenge. Blood specimens for culture were collected from mice 1–2 hours after bacterial challenge. For passive immunization against lethal pneumonia, mice were injected intraperitoneally with 1 mg of rabbit IgG 24 hours (or 24 hours and 4 hours) before bacterial inoculation. For T-cell–depletion studies, actively immunized mice were injected intraperitoneally with either 500 µg of rat anti-mouse CD4 (clone GK 1.5) or rat anti-mouse CD8a (clone 53–6.7) mAbs 72 hours and 24 hours before intranasal challenge with S. aureus Newman. Depletion of CD4+ or CP8+ cells was verified by flow cytometric analysis of splenic lymphocytes.

RESULTS

Synthesis of S. aureus CPs in E. coli
The S. aureus CPs are assembled on the bacterial membrane carrier lipid undecaprenyl pyrophosphate by a conserved pathway that shares homology to the polymerase-dependent
pathway of O polysaccharide synthesis in gram-negative bacteria [29]. O antigen assembly is initiated by the transfer of a sugar phosphate from a uridine diphosphate donor to undecaprenyl phosphate. The lipid-linked O antigen is assembled at the cytoplasmic side of the inner membrane by sequential action of different glycosyltransferases. The glycolipid is then flipped to the periplasmic space and polymerized. By replacing the O antigen ligase WaaL with the oligosaccharyltransferase PglB, the polymerized O antigen can be transferred to a protein carrier of choice rather than to the lipid A core [16, 30].

To synthesize *S. aureus* CP5 or CP8 in an *E. coli* strain deficient in O antigen production, we constructed plasmid-based chimeric genetic clusters containing genes with known function from *S. aureus* and *P. aeruginosa* (Figure 1A). The gene clusters were designed based on the similar structures of *S. aureus* CPs and the *P. aeruginosa* O11 antigen, as each contains a FucNAc disaccharide as part of the trisaccharide repeating unit [31, 32]. In combination with *E. coli* monosaccharide biosynthesis genes, the enzymes encoded by these genes were predicted to synthesize an undecaprenyl pyrophosphate-linked CP5 or CP8 polymer consisting of repeating trisaccharide units (Figure 1B). The recombinant plasmids were transformed into an *E. coli* strain with a deletion in the O-antigen ligase WaaL, and the bacterial glycolipids were extracted. The polysaccharides were released from the carrier lipid by mild acid treatment, labeled by 2-aminobenzamide (2-AB), and separated by high-performance liquid chromatography. Single repeating subunits of CP5 (Figure 2A) and CP8 (Figure 2B) were collected and characterized using MALDI-Q TOF/TOF analysis. The major ion seen at a mass-to-charge ratio of 794.3 was subjected to tandem mass spectrometry. The series of fragment ions were in agreement with the expected ions of the Na-adduct of the
Enzymatic Synthesis of S. aureus Bioconjugate Vaccines in E. coli

To produce S. aureus vaccines in E. coli, the lipid-linked CPs were expressed in the presence of a protein carrier antigen and PglB. This allowed transfer of the polysaccharide from the carrier lipid to Asn residues within the consensus sequence D-X-N-X-S/T [20] of the protein antigen. E. coli cells expressing the CP5 or CP8 gene clusters, Epa containing 2 glycosylation consensus sequences, and PglB were cultivated. Expression of Epa and PglB was induced, and glycosylated Epa was extracted and purified. SDS-PAGE revealed a ladder of bands between 90 and 170 kDa that reacted with antibodies to Epa and CP5 (Figure 2G) or Epa and CP8 (Figure 2H), indicating variable glycosylation of Epa with S. aureus CP antigens.

A second-generation vaccine system was designed to glycosylate a staphylococcal protein antigen (Hla) in E. coli. HlaH35L containing a glycosylation consensus sequence at amino acid 130 was constructed. E. coli cells carrying genes encoding CP5 biosynthesis, HlaH35L, and PglB were cultivated. Expression of HlaH35L and PglB was induced, and CP5-HlaH35L was purified. The CP5-HlaH35L glycoconjugate subjected to SDS-PAGE revealed a ladder of bands between 55 and 70 kDa that reacted with antibodies to Hla and CP5 (Figure 2I). This finding confirms that HlaH35L can be glycosylated with CP5.

Immunogenicity of Bioconjugate Vaccines in Mice

Mice were immunized with CP5-Epa, CP8-Epa or CP5-HlaH35L. The CP5-Epa vaccine showed optimal immunogenicity at 0.2–1 µg CP5/mouse (Figure 3A), and CP8-Epa showed good immunogenicity at 0.2 µg CP8 (Figure 3B). CP5-HlaH35L was immunogenic at CP5 concentrations of 0.2 and 2 µg/mouse (Figure 3C). Because the optimal HlaH35L dose was 20 µg/mouse (Figure 3D), a 2 µg CP5–20 µg HlaH35L vaccine was chosen for further evaluation.

Bioconjugate Vaccines Elicit Functional Antibodies

In the presence of HL60 phagocytic cells and serum complement, rabbit IgG raised to CP5-Epa or CP5-HlaH35L was opsonic for CP5\(^\ast\) S. aureus strains Reynolds and Newman (Figure 4A). IgG concentrations of ≥1 µg/mL resulted in ≥50% killing of the staphylococcal inoculum. Similarly, serum from mice immunized with CP5-Epa or CP5-HlaH35L showed OPK activity against CP5-producing S. aureus (Supplementary Figure 1A). Rabbit antibodies to CP5-Epa were also opsonic for S. aureus strains Reynolds (CP5) and Newman when human neutrophils were included as the phagocytic cell source (Figure 4B and 4C). MRSA strains USA100 and USA200 (both CP5\(^\ast\)) were also killed in the presence of CP5-Epa antibodies, human neutrophils, and serum complement (Figure 4D and 4E). CP5 antibodies were not opsonic for Reynolds (CP8) (Figure 4F). The Reynolds (CP\(^\ast\)) strain was killed by neutrophils and complement without added antibodies (Figure 4F). Rabbit CP8-Epa IgG was opsonic for S. aureus Reynolds strain (CP8) and MRSA strain ST80 (Figure 4G) at concentrations of ≥1 µg/mL. Likewise, mouse CP8-Epa antisera showed good opsonic activity (Supplementary Figure 1B) against CP8\(^\ast\) S. aureus strains.
Figure 4. *Staphylococcus aureus* glycoconjugate vaccines elicited functional antibodies. A, Rabbit immunoglobulin G (IgG; 10, 1, or 0.1 µg/mL) to either CP5-Epa or CP5-HlaH35L was opsonic for serotype 5 *S. aureus* strains Reynolds (CP5) and Newman in HL-60 opsonophagocytic killing (OPK) assays (*n* = 3), whereas antibodies to Hla and *Shigella* O1-Epa were nonopsonic. B–E, OPK assays performed with human neutrophils revealed that rabbit antibodies to CP5-Epa were opsonic for Reynolds (CP5; B), Newman (C), USA100 (D), and USA200 (E) at concentrations as low as 1 µg/mL. Rabbit antibodies to the control bioconjugate *Shigella* O1-Epa vaccine lacked opsonic activity. OPK assays were performed as described (26) with CP5-Epa (concentrations shown are µg/mL), human polymorphonuclear leukocytes (PMNs), and guinea pig serum as a complement (C′) source. F, Specificity of the assay was shown by the inability of CP5-Epa IgG to opsonize a serotype 8 strain (Reynolds [CP8]) for phagocytic killing. The capsule-negative Reynolds (CP8) strains were killed by PMNs + C′ alone (with or without capsular antibodies). G, Rabbit IgG (≥1 µg/mL) to CP8-Epa was opsonic for serotype 8 *S. aureus* strains Reynolds (CP8) and methicillin-resistant *S. aureus* strain ST80. No bacterial killing was observed in samples lacking antibodies or with *Shigella* 2a-Epa IgG. H, Sera from mice (n = 7–16) immunized with 20 µg HlaH35L or 2 µg CP5-20 µg HlaH35L neutralized the lytic activity of Hla toward rabbit erythrocytes. The percentage hemolysis was calculated in comparison to 100% lysis of erythrocytes with 4 U/mL of native Hla. Sera from mice immunized with HlaH35L showed greater in vitro neutralization activity than sera from mice given CP5-HlaH35L. Lack of overlap in the 95% confidence intervals between the 50% lysis titers indicates differences significant at a *P* value of <.05. Bars represent standard errors of the mean (SEM). Abbreviation: CFU, colony-forming units.
Functional antibodies to Hla neutralize its lytic activity. As shown in Figure 4H, mouse sera against either HlaH35L or CP5-HlaH35L neutralized the in vitro lytic activity of native Hla. Mice immunized with 20 µg HlaH35L showed higher neutralizing titers than mice given 2 µg CP5-20 µg HlaH35L.

### Bioconjugate Vaccines Protect Mice Against S. aureus Bacteremia

Mice vaccinated with CP5-Epa or the Shigella O1-Epa vaccine were challenged intraperitoneally with S. aureus Reynolds (CP5). Mice given CP5-Epa were protected against bacteremia (Figure 5A), renal abscess formation (Figure 5B), and weight loss (Figure 5C), compared with mice given the irrelevant Shigella vaccine. Similarly, animals immunized with CP8-Epa and challenged with Reynolds (CP8) showed a significant reduction in bacteremia (Figure 5D).

The second-generation bioconjugate vaccine contained a staphylococcal toxoid (HlaH35L) glycosylated with CP5. CP5-HlaH35L was protective against bacteremia (Figure 5E) and associated weight loss (Figure 5F) provoked by challenge with Reynolds (CP5). There was an inverse correlation between CP5 antibody levels and bacteremia levels in individual mice (Figure 5G), confirming that protection was mediated by vaccine-induced antibodies.

### CP5-HlaH35L Protects Against Lethal Pneumonia Caused by CP5+ and CP8+ S. aureus

Mice were vaccinated with HlaH35L, CP5-HlaH35L, CP5-Epa, or Shigella 2a-Epa and challenged intranasally with CP5+ strain Newman. Mice immunized with HlaH35L or CP5-HlaH35L were protected against lethal pneumonia. CP5 antibodies did not mediate protection, since mice vaccinated with CP5-Epa succumbed to the infection, similar to the mice given Shigella 2a-Epa (Figure 6A). The HlaH35L and CP5-HlaH35L vaccines also protected against lethal pneumonia induced by the CP8+ strain USA300 LAC (Figure 6B) and the CP8+ MRSA strain ST80 (Figure 6C). Despite the fact that HlaH35L elicited a higher neutralizing antibody response to Hla than CP5-HlaH35L.
Depletion of CD4+ or CP8+ T cells was verified by flow cytometric analysis of splenocytes from treated animals. Control CP5-HlaH35L immunized mice and those subjected to T-cell depletion showed similar survival in the lethal pneumonia model, whereas mice vaccinated with *Shigella* 2a-Epa succumbed to the infection (Figure 6D). These results indicate that T cells are not critical for CP5-HlaH35L-mediated protection against lethal *S. aureus* pneumonia.

**Antibodies to Bioconjugate Vaccines Protected Against Bacteremia and Lethal Pneumonia**

One day before intraperitoneal challenge with *S. aureus*, mice were passively immunized intravenously with rabbit IgG to CP5-Epa, CP8-Epa, or CP5-HlaH35L. Compared with *Shigella* O1-Epa antibodies, CP5-Epa antibodies were protective against bacteremia induced by Reynolds (CP5; Figure 7A) and by MRSA strain USA200 (Figure 7B). Similarly, Reynolds (CP8) bacteremia was significantly reduced by antibodies to CP8-Epa (Figure 7C). Antibodies to CP5-HlaH35L reduced bacteremia induced by MRSA strain USA100 (Figure 7D), Newman (Figure 7E), and Reynolds (CP5; Figure 7F). The protection was CP specific because antibodies to either CP5-Epa or CP5-HlaH35L reduced bacteremia, whereas antibodies to *S. aureus* HlaH35L or *Shigella* 2a-Epa provided no protection (Figure 7F).

Passive immunization with CP5-HlaH35L IgG administered intraperitoneally 24 hours before intranasal bacterial challenge provided limited protection against lethal pneumonia (Figure 7G) induced by strain Newman. However, when a second dose of IgG was given 4 hours before bacterial inoculation, 90% of the mice given CP5-HlaH35L survived a lethal inoculum (Figure 7H).

**DISCUSSION**

The increasing prevalence of *S. aureus* infection in the hospital and community and the expanding resistance of *S. aureus* to antibiotics has emphasized the need for a preventive vaccine against this microbe. However, development of an effective staphylococcal vaccine has remained elusive. Vaccination with single-component vaccines based on CPs or *S. aureus* iron surface determinant B failed to protect patients from invasive disease in phase 3 clinical trials [6, 7, 34, 35]. Similarly, passive immunization strategies targeting clumping factor A or lipoteichoic acid did not prevent staphylococcal sepsis in premature neonates [7]. Current endeavors are focused on the preparation of vaccines that target multiple staphylococcal virulence factors. In addition to the importance of antibodies in mediating toxin neutralization and opsonophagocytic killing by neutrophils, T-cell-based immunity has recently been shown in animal infection models to be critical for vaccine-mediated protection induced by certain protein antigens [7, 36–38].

Because opsonophagocytic killing by neutrophils is a key component for host clearance of *S. aureus*, we have targeted staphylococcal CPs, which elicit opsonic antibodies. Production of glycoconjugate vaccines is complex and expensive, requiring the preparation of recombinant proteins and extraction and
purification of complex polysaccharides. Because of the nonspecific nature of chemical conjugations, chemically conjugated vaccines are heterogeneous, variable from batch to batch, and often produced in low yield. Moreover, conventional conjugation of polysaccharides to protein antigens requires denaturing chemicals that may affect the protein carrier or certain labile polysaccharides, resulting in alteration of critical epitopes.

We have developed a novel technology that allows the conjugation of an S. aureus CP to a relevant S. aureus protein without the risk of protein denaturation. The Campylobacter oligosaccharyl transferase PglB is able to transfer an oligosaccharide to a specific protein consensus sequence [20], thereby allowing the production of glycoproteins in bacterial cells. This protein glycosylation system has been functionally transferred into E. coli [15]. By using this glycosylation machinery, a variety of polysaccharides can be transferred to recombinant proteins, allowing the production of bioconjugates that can be exploited as novel vaccines. Bioconjugate vaccine lots are homogeneous, and no free polysaccharide is present during the production to inhibit T-cell-dependent immune responses. Because the bioconjugate is produced in E. coli, growth of toxic organisms for polysaccharide extraction is not required.

In this study, we demonstrated production, purification, and efficacy of CP5-Epa and CP8-Epa bioconjugate vaccines. In addition, we showed that the disaccharide intermediate of P. aeruginosa O11 antigen can serve as substrate for S. aureus glycosyltransferases, showing for the first time that glycosyltransferases of gram-positive and gram-negative bacteria can be combined. The bioconjugate vaccines elicited opsonic antibodies in mice and rabbits, and active and passive immunization strategies protected mice against experimental bacteremia. The second-generation bioconjugate vaccine (CP5-HlaH35L) was an important proof-of-concept product to show the potential of covalently linking protein and polysaccharide antigens from the same microbe. Like animals given CP5-Epa, mice immunized with CP5-HlaH35L were protected against bacteremia provoked by several CP5+ S. aureus isolates. Importantly, the CP5-HlaH35L vaccine also protected mice against lethal pneumonia induced by serotype 5, serotype 8, or capsule-negative S. aureus strains. Thus, the CP5-HlaH35L bioconjugate vaccine showed protective efficacy against bacteremia (mediated by CP5 antibodies) and lethal pneumonia (mediated by HlaH35L antibodies).

This novel glycoengineering approach to conjugate vaccine development could revolutionize the industry. The trivalent...
S. aureus vaccine candidate (described herein) composed of CP5, CP8, and HlAβ555L elicits functional antibodies and broadly protects in different animal models. Glycosylation of an S. aureus surface protein with CP8 has been accomplished, and it is currently undergoing production and testing. Glycoengineering technology enables the development of well-defined, novel, and effective vaccines against microbial pathogens such as S. aureus, for which protein or polysaccharide antigens alone are not sufficient to provide broad protection. In addition, conjugation of capsular antigens to protein antigens allows the reduction of components to be injected compared to a vaccine that contains separate capsular conjugate and protein components.

Supplementary Data

Supplementary materials are available at The Journal of Infectious Diseases online (http://jid.oxfordjournals.org/). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyrighted. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Notes

Acknowledgments. We thank Shannon Brennan, Justin Owumi, Patrick Tavares, Sacha Keller, Fabian Meyer, Stefanie Balada, Micha Tobler, and Markus Müller, for technical assistance; Reka Szathmary, for initial engineering technology enables the development of well-defined, novel, and effective vaccines against microbial pathogens such as S. aureus, for which protein or polysaccharide antigens alone are not sufficient to provide broad protection. In addition, conjugation of capsular antigens to protein antigens allows the reduction of components to be injected compared to a vaccine that contains separate capsular conjugate and protein components.

Supplementary Data

Supplementary materials are available at The Journal of Infectious Diseases online (http://jid.oxfordjournals.org/). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyrighted. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Notes

Acknowledgments. We thank Shannon Brennan, Justin Owumi, Patrick Tavares, Sacha Keller, Fabian Meyer, Stefanie Balada, Micha Tobler, and Markus Müller, for technical assistance; Reka Szathmary, for initial engineering technology enables the development of well-defined, novel, and effective vaccines against microbial pathogens such as S. aureus, for which protein or polysaccharide antigens alone are not sufficient to provide broad protection. In addition, conjugation of capsular antigens to protein antigens allows the reduction of components to be injected compared to a vaccine that contains separate capsular conjugate and protein components.

Potential conflicts of interest. M. W., M. K., G. L., A. F., C. A., M. B., J. Q., V. G., P. C., and M. S. are employees of GlycoVaxyn, which has secured exclusive, worldwide rights from the Swiss Federal Institute of Technology to its proprietary technology and has submitted patent applications in the United States on capsular gram-positive bacteria bioconjugate vaccines. J. C. L. is a paid consultant on vaccine development for Sanofi Pasteur and Pfizer and receives research support from Centegen. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References


